50th week of 2013 patent applcation highlights part 47 |
Patent application number | Title | Published |
20130331383 | NITROFURAN COMPOUNDS FOR THE TREATMENT OF CANCER AND ANGIOGENESIS - The invention is directed to the synthesis and use of nitrofuran compounds, especially Nifurtimox, as medicaments to treat cancer, especially neuroblastoma, and to inhibit angiogenesis. The invention also provides compositions, unit dosage forms, and kits comprising the compounds. | 2013-12-12 |
20130331384 | FIRMOCIDIN, AN ANTIMICROBIAL MOLECULE PRODUCED BY STAPHYLOCOCCUS EPIDERMIDIS - The disclosure provides for novel antimicrobial agents, methods of making, and methods of use thereof. | 2013-12-12 |
20130331385 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC, OTIC, OR NASAL INFECTIONS - The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections. | 2013-12-12 |
20130331386 | METHODS FOR TREATING VASCULAR LEAK SYNDROME - Disclosed are methods for treating Vascular Leak Syndrome. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, inter alia, sepsis, lupus, irritable bowel disease. Yet further disclosed are methods for treating renal cell carcinoma and melanoma. Still further disclosed are methods for reducing metastasis of malignant cells and/or preventing the proliferation of carcinoma cells via spreading due to vascular leakage. | 2013-12-12 |
20130331387 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS - Disclosed is a compound of formula (I), wherein Z, m and R | 2013-12-12 |
20130331388 | Combinations of Therapeutic Agents for use in the Treatment of Neurodegenerative Diseases - The present invention relates to a combination of an allosteric mTOR inhibitor and a catalytic mTOR inhibitor for use in the prevention or treatment of neurodegenerative diseases, for example Huntington's Disease, and products and pharmaceutical compositions comprising such a combination for use in the prevention or treatment of such neurodegenerative diseases. | 2013-12-12 |
20130331389 | Methods and Compositions for Cardiomyocyte Replenishment by Endogenous and Progenitor Stem Cells - Disclosed herein are methods and compositions for replenishing injured and/or damaged cardiomyocytes in a subject by inducing, increasing, and/or enhancing the differentiation of endogenous stem and progenitor cells in the subject. | 2013-12-12 |
20130331390 | Nitrogen-Containing Biphenyl Compounds, Pharmaceutical Compositions of Same, Preparation Methods and Anti-HIV-1 Uses Thereof - Nitrogen-containing biphenyl compounds as represented by formula (I), pharmaceutically acceptable salts or derivatives thereof, pharmaceutical compositions, and preparation methods therefore, and anti-HIV-1 use of the compound. Each substituent group in formula (I) is as defined in the description. | 2013-12-12 |
20130331391 | VIRAL POLYMERASE INHIBITORS - Compounds of formula I: | 2013-12-12 |
20130331392 | CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF - The invention provides cycloalkyl guanidine compounds that inhibit F | 2013-12-12 |
20130331393 | THERAPEUTIC FORMULATION AND METHODS OF TREATMENT - The present disclosure relates pharmaceutical formulations comprising hydralazine in the treatment of eye diseases and conditions with the formulations. The present disclosure also related to methods of preparing the pharmaceutical formulations. | 2013-12-12 |
20130331394 | TREATING SCHIZOPHRENIA - Methods of identifying new treatments for schizophrenia, and the use of the same. | 2013-12-12 |
20130331396 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE - Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis). | 2013-12-12 |
20130331397 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity. | 2013-12-12 |
20130331398 | MODULATION OF UBIQUITINATION OF SYNAPTIC PROTEINS FOR THE TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISORDERS - The instant invention is based, at least in part, on a newly-identified proteasome-independent signaling function of ubiquitinated PSD-95. Mdm2 inhibitors, Mdm4 inhibitors, PSD-95 inhibitors, and/or enantiomers and/or derivatives thereof de-crease endocytosis via preventing PSD-95 ubiquitination, and thereby increase AMPAR, NMDAR, D1 dopamine receptor surface expression in response to a given stimulus (e.g., NMDA, Aβ). Accordingly, the invention provides methods for modulating AM-PARS, NMDARs, or D1 dopamine receptors in a neuronal cell by contacting the neuronal cell with an Mdm2 and/or Mdm4 inhibitor or PSD-95 inhibitor and/or enantiomers and/or derivatives thereof. Mdm2 and/or Mdm4 inhibitors decrease the enzymatic activity of the respective proteins, and/or interactions with their respective substrates. Mdm2 and Mdm4 inhibitors and/or PSD-95 inhibitors of the invention are contemplated for use in the treatment of neurological disorders, neurodevelopmental disorders, and psychiatric disorders. The invention also provides methods to screen for new Mdm2 and Mdm4 inhibitors and PSD-95 inhibitors and/or enantiomers and/or derivatives thereof. | 2013-12-12 |
20130331399 | Treatment of Motor and Movement Disorder Side Effects Associated with Parkinson's Disease Treatments - This invention provides methods of treating motor disorder side effects associated with the administration of levodopa to a subject having Parkinson's disease, by administering a dose of eltoprazine or a pharmaceutically acceptable acid addition salt thereof. In particular, the invention provides methods for reducing dyskinesia associated with Parkinson's disease treatments, and effective doses of eltoprazine or a pharmaceutically acceptable acid addition salt thereof. | 2013-12-12 |
20130331400 | METHOD FOR PRODUCING INDIGO-PLANT LEAF EXTRACT - An object of the present invention is to provide a tryptanthrin-containing indigo-plant leaf extract particularly suitable for application to the skin. The present invention provides a method for producing a tryptanthrin-containing indigo-plant leaf extract, the method comprising filtering a mixture of a concentrated ethanol extract of indigo-plant leaves and a polyhydric alcohol, and collecting the filtrate. The present invention further provides an indigo-plant leaf extract produced by this method. | 2013-12-12 |
20130331401 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates - The invention provides novel halogenated pyrazolo[1,5-a]pyrimidines of formula (I) wherein R, R | 2013-12-12 |
20130331402 | DOSING REGIMEN ASSOCIATED WITH LONG-ACTING INJECTABLE PALIPERIDONE ESTERS - The present application provides a method for treating patients in need of psychiatric treatment, wherein said patient misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides a method for treating psychiatric patients in need of a switching treatment to paliperidone palmitate in a sustained release formulation. | 2013-12-12 |
20130331403 | POLYMORPHIC FORMS OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACE- TIC ACID AND USES THEREOF - Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented. | 2013-12-12 |
20130331404 | Methods and Compositions for Inhibition of Polymerase - The present invention is directed to methods and compositions for inhibition of viral nucleic acid polymerases, such as RNA and DNA polymerases, and methods and compositions that are useful for treating viral infections in subjects. The methods comprise administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. The composition or method may optionally comprise one or more additional anti-viral agents. | 2013-12-12 |
20130331405 | PIK3CA Mutation Status and SASH1 Expression Predicts Synergy Between Lapatinib and an AKT Inhibitor in HER2 Positive Breast Cancer - Methods for identifying a cancer patient, such as a breast cancer patient, suitable for treatment with a 4-anilinoquinazoline kinase inhibitor, such as lapatinib, and an AKT inhibitor, comprising detecting modulated expression of HER2 (ERBB2) and SASH1 or protein encoded thereof and detecting PIK3CA mutation status. High levels of expression in HER2 and high levels of SASH1 and/or positive PIK3CA mutation status indicate a patient that is suitable for treatment with a 4-anilinoquinazoline kinase inhibitor, such as lapatinib and an AKT inhibitor. | 2013-12-12 |
20130331406 | NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES - The present invention relates to novel compounds, their pharmaceutically acceptable salts, and their isomers, steroisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses pharmaceutically acceptable compositions of said compounds and process for preparing novel compounds. The invention further relates to the use of the above-mentioned compounds for the preparation of medicament for use as pharmaceuticals. | 2013-12-12 |
20130331407 | INHIBITORS OF PROTEIN KINASES - The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases. | 2013-12-12 |
20130331409 | CONDENSED HETEROCYCLIC COMPOUND - The present invention provides a compound having a superior PDE10A inhibitory action and use thereof. The compound is a compound represented by the following formula (I): | 2013-12-12 |
20130331410 | 2,3-DIHYDROFURO[2,3-c]PYRIDIN-2-YLPIPERIDINE DERIVATIVES - The present invention relates to compounds of general formula I, | 2013-12-12 |
20130331411 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS - The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof. | 2013-12-12 |
20130331412 | Pharmaceutical Compositions and Administrations Thereof - The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. | 2013-12-12 |
20130331413 | DEFENSIN-LIKE MOLECULES AS NOVEL ANTIMICROBIAL AGENTS - Disclosed are compositions and methods for treating and/or preventing infections in mammals, by administering to a mammal a therapeutically effective amount of at least one defensin-like molecule, e.g., in a composition that includes such molecule. Also disclosed are kits that include such molecules, or compositions that include such molecules, as well as instructions for using such molecules to treat a mammal. | 2013-12-12 |
20130331414 | Inhibitors of Retroviral Replication - Methods for preventing or treating retroviral infection, such as human immunodeficiency virus, in vivo utilize transcriptional inhibitory compounds. These include cortistatin A and analogs of the cortistatin family. | 2013-12-12 |
20130331415 | COMPOSITIONS COMPRISING WNT INHIBITORS FOR TREATING CANCER - The present invention is directed to compositions for the treatment of cancer, in particular for the treatment of myeloma, lymphoma and leukaemia. The present invention is further directed to the use of said compositions for the manufacture of a medicament for the treatment of cancer and for the use of said compositions in a medicament for treating cancers in animals and humans. | 2013-12-12 |
20130331416 | DOSAGE REGIMEN FOR COMT INHIBITORS - The invention relates to the use of an oxodiazolyl compound (I) for the preparation of a medicament for the prevention or treatment of central and peripheral nervous system associated disorders, wherein said medicament is administered according to a dosing regimen having a dosing periodicity ranging from about twice a day to about once every other day. | 2013-12-12 |
20130331417 | INSECTICIDAL MIXTURES WITH IMPROVED PROPERTIES - The present invention relates to novel pesticidal compositions comprising the crystalline modification I of 4-{[(6-chloropyrid-3-yl)methyl](methyl)amino} furan-2(5H)-one and a insecticide, acaricide or nematicide that show surprisingly good insecticidal, acaricidal, nematicidal and fungicidal activities. In particular, these compositions are suited for the treatment of seed. | 2013-12-12 |
20130331418 | Methods for Preventing Flea Allergy Dermatitis in Companion Animals - Methods for reducing the incidence of flea allergy dermatitis (FAD) in a companion animal are disclosed, the methods directed to inhibiting blood feeding by ectoparasites on a companion animal. The methods of the present invention involve administering a pesticide composition comprising cyphenothrin to a companion animal, specifically dogs and cats, in doses and proportions which are parasiticidally effective against a variety of ectoparasites, and in formulations which are convenient for topical application to the animal's skin, preferably localized over a small surface area. Such methods are useful in preventing and/or reducing the incidence of flea allergy dermatitis. | 2013-12-12 |
20130331419 | MINERALOCORTICOID RECEPTOR ANTAGONISTS - Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and the pharmaceutical compositions which comprise compounds of the formula (I) are disclosed too. | 2013-12-12 |
20130331420 | TETRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME - Described herein are tetrazole compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tetrazole compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 2013-12-12 |
20130331421 | SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS - Compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds, or salts or solvates thereof, are provided. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions of substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may find use in the prevention and/or treatment of a variety of conditions, including prostate cancer, Parkinson's disease, Alzheimer's disease, and others. | 2013-12-12 |
20130331422 | METHODS AND DEVICES FOR USING ISOPERILLY ALCOHOL - The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of an isomer or analog of monoterpene or sesquiterpene (or its derivative), such as an isoperillyl alcohol. The present invention also provides for a method of treating a disease comprising the step of administering to a patient a therapeutically effective amount of a derivative of an isomer or analog of monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The derivative may be an isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection. | 2013-12-12 |
20130331423 | Form of Administration of Enkephalinase Inhibitor - The present invention relates to a new formulation of an enkephalinase inhibitor, such as racecadotril or dexecadotril, the process for the preparation thereof, and the use thereof in the treatment of diarrhoea. | 2013-12-12 |
20130331424 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - Described herein are antimicrobial compounds identified via a high-throughput inhibitor screen of the in vitro activity of MipZ, which is an ATPase that regulates division site placement in | 2013-12-12 |
20130331425 | POLYMER-SUNITINIB CONJUGATES - The invention relates to (among other things) polymer-sunitinib conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over sunitinib in unconjugated form. | 2013-12-12 |
20130331426 | pH-SENSITIVE COMPOSITIONS FOR DELIVERY OF BETA LAPACHONE AND METHODS OF USE - Disclosed herein are compounds comprising a polymer conjugated with a pH-sensitive prodrug of beta-lapachone, wherein the compound is capable of forming a micelle, and wherein the pH-sensitive prodrug comprises a pH-sensitive linker selected from the group consisting of: an aryl imine and an aliphatic imine. Also provided are micelles comprised of such polymer-prodrug conjugates. Further provided are methods for treating cancer with the micelles. | 2013-12-12 |
20130331427 | METHODS OF STIMULATING CELLULAR GROWTH, SYNAPTIC, REMODELING AND CONSOLIDATION OF LONG-TERM MEMORY - The present invention provides methods of slowing or reversing the loss of memory and learning comprising the steps of contacting an effective amount of a PKC activator with a protein kinase C (PKC) in a subject identified with memory loss slowing or reversing memory loss. The present invention provides methods of stimulating cellular growth, neuronal growth, dendritic growth, dendritic spine formation, dendritic spine density, and the translocation of ELAV to proximal dendrites, and synaptic remodeling. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC. | 2013-12-12 |
20130331428 | TOPICAL COMPOSITIONS CONTAINING A RETINOID OF THE OIL-IN-WATER EMULSION TYPE - A composition in the form of an oil in water emulsion, preferably without emulsifier, is described. The composition can include, in a physiologically acceptable environment, at least one new retinoid. Also described, is the method of preparing the composition and its use in cosmetics and dermatology. | 2013-12-12 |
20130331429 | AMINOTETRALINE DERIVATIVES - The present application relates generally to amino tetraline derivative compounds and methods of use, specifically, embodiments including compounds of formula (I) described herein, pharmaceutically acceptable salts and solvates. More specifically, this application relates to amino tetraline derivative compounds and uses of such compounds producing medicaments for the treatment of various disease and conditions including movement disorders and disorders of the central nervous system. | 2013-12-12 |
20130331430 | Compositions And Methods For Inhibiting Expression Of The PCSK9 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by PCSK9 gene expression and the expression of the PCSK9 gene using the pharmaceutical composition; and | 2013-12-12 |
20130331431 | ANALGESIC MEDICATION - An analgesic medication includes an oligonucleotide being a double strand RNA comprising 18 to 70 base pairs, and a pharmaceutical acceptable vehicle for delivering the said oligonucleotide into cells, wherein a dosage of the oligonucleotide in the analgesic is 50 μg to 200 μg/kg per time, and the pharmaceutical acceptable vehicle is selected from a group of polyethyleneimine, lipofectamine and iFect. | 2013-12-12 |
20130331432 | METABOLIC GENE, ENZYME, AND FLUX TARGETS FOR CANCER THERAPY - A novel pathway in cancer cell metabolism is identified. Targeting of any gene, protein, or enzyme that modulates activity or flux through this pathway, including, but not limited to IDH1, isocitrate dehydrogenase 2 (IDH2), aconitase 1 (ACO1), aconitase 2 (ACO2), glutaminase (GLS), glutamate dehydrogenase (GDH) and transaminase, provides effective means of inhibiting tumor growth. | 2013-12-12 |
20130331433 | MIRNA MODULATORS OF THERMOGENESIS - Provided are novel methods and compositions for the modulation of thermogenesis. Such methods are particularly advantageous in that they allow for the reduction of body fat in a subject without the subject having to adjust their caloric intake through dieting, modify their physical activity or undergo bariatric surgery. Accordingly, the methods of the invention are particularly useful for treating or preventing obesity. Also provided are methods of screening for novel agents that modulate the activity of thermogenic regulators. | 2013-12-12 |
20130331434 | METHODS FOR MODULATING FACTOR 12 EXPRESSION - Disclosed herein are methods for decreasing Factor 12 and treating or preventing thromboembolic conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 12 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, and mesenteric thrombosis. Methods for inhibiting Factor 12 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism. | 2013-12-12 |
20130331435 | ANTISENSE MODULATION OF KINESIN-LIKE 1 EXPRESSION - Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided. | 2013-12-12 |
20130331436 | MICRORNAS AS NEW THERAPEUTIC TARGETS FOR THE PREVENTION AND/OR TREATMENT OF RETINOPATHY - Methods and compositions are disclosed to identify plasma and vitreous microRNA (miRNA) signatures of diabetic retinopathy (DR), and then as diagnostic biomarkers for the onset and progression of DR. | 2013-12-12 |
20130331437 | METHODS FOR MODULATING THE EXPRESSION AND AGGREGATION OF CAG-EXPANDED GENE PRODUCT IN CELLS AND METHODS FOR IDENTIFYING AGENTS USEFUL FOR DOING THE SAME - This invention provides a method for modulating the expression of a first gene in a cell wherein the first gene is one containing more than 36 CAG trinucleotide repeats and encoding a protein that form polyglutamine-mediated protein aggregation. Suppression of the first gene is achieved by reducing the expression of SPT4 gene or SUPT4H gene. It can also be achieved by inhibiting the formation of a Spt4/Spt5 complex or a Supt4h/Supt5h complex. Also provided is a method for identifying an agent useful for modulating the expression and aggregation of CAG-expanded gene product, or treating a polyglutamine disease such as Huntington's disease. | 2013-12-12 |
20130331438 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 2013-12-12 |
20130331439 | Methods for Diagnosing Stomach Cancer Using MicroRNAs - Described herein are methods for diagnosing stomach cancer using microRNAs. Also described are methods and compositions for the diagnosis and treatment of solid cancers. Methods of identifying inhibitors of tumorigenesis are also provided. | 2013-12-12 |
20130331440 | UCP1 (THERMOGENIN) - INDUCING AGENTS FOR USE IN THE TREATMENT OF A DISORDER OF THE ENERGY HOMEOSTASIS - The present invention relates to compositions comprising an agent, like a polynucleotide, which induces or upregulates expression of UCP1 for use in treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject. The present invention also relates to a method of treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject comprising administrating a composition comprising a polynucleotide which induces or upregulates expression of UCP1. | 2013-12-12 |
20130331441 | Cell Line, System and Method for Optical Control of Secondary Messengers - A variety of methods, devices and compositions are implemented for light-activated molecules. One such method is implemented for generating secondary messengers in a cell. A nucleotide sequence for expressing a chimeric light responsive membrane protein (e.g., rhodopsin) is modified with one or more heterologous receptor subunits {e.g., an adrenergic receptor (alpha1, Beta2)}. The light responsive membrane protein is expressed in a cell for producing a secondary messenger in response to light. | 2013-12-12 |
20130331442 | Combination Therapy for Cancer - An agent comprises a vector having a functional gene, a prodrug which can be converted into a cytotoxic agent by an expression product of the gene, and another cytotoxic agent, as a combined preparation for simultaneous, sequential or separate use in the therapy of cancer or of a disease characterised by an impaired mismatch repair (MMR) pathway, wherein the dosage regimen comprises beginning another cytotoxic agent therapy no later than 7 days after the prodrug therapy has finished. | 2013-12-12 |
20130331443 | MULTI-ARM POLYMERIC PRODRUG CONJUGATES OF TAXANE-BASED COMPOUNDS - Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of taxane-based compounds and/or fluorinated forms thereof. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the taxane-based compound is achieved. | 2013-12-12 |
20130331444 | TREATMENT OF COGNITIVE DISORDERS ASSOCIATED WITH ABNORMAL DENDRITIC SPINES USING PKC ACTIVATORS - The present disclosure provides methods of treating a cognitive disorder associated with abnormal dendritic spines, such as Fragile X Syndrome, Fragile X Associated Tremor/Ataxia Syndrome, autism, or mental retardation, using PKC activators. | 2013-12-12 |
20130331445 | Picropodophyllin Monohydrate or Polymorph A in Cancer Therapy - The invention related to picropodophyllin monohydrate as well as to picropodophyllin polymorph A for use in therapy, such as their use in cancer therapy. | 2013-12-12 |
20130331446 | 3-ACYL-INGENOLS II - The invention relates to compounds of general formula I, (I), wherein R is wherein R is aryl substituted by R3; or R is (C3-Ci3)-cycloalkyl, (C3-Ci3)-cycloalkenyl or (C7-Ci3)-cycloalkynyl optionally substituted by R4; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis. | 2013-12-12 |
20130331447 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2013-12-12 |
20130331448 | COMPOSITIONS COMPRISING 20-CARBON FATTY ACIDS AND METHODS OF MAKING AND USING SAME - The present disclosure provides a process for producing 20-carbon fatty acids from a plant seed oil, the process comprising: a) providing a plant seed oil comprising fatty acids, wherein the fatty acids include 18-carbon fatty acids; and b) elongating the fatty acids by two carbon atoms to produce a composition comprising 20-carbon fatty acids. | 2013-12-12 |
20130331449 | SUPPLEMENT COMPOSITION AND METHOD OF USE TO TREAT ANHIDROSIS - The present invention relates to a dietary supplement composition made of: linolenic expeller pressed soybean oil in the range of 65%-85%, Omega 3 (18/12) fish oil 15%-35%, and 1%-20% alpha-tocopherol and a method to use this composition to supplement the diet of a domestic animal, such as a canine or an equine. | 2013-12-12 |
20130331450 | CLASS II HMG-COA REDUCTASE INHIBITORS AND METHODS OF USE - Disclosed are compositions and methods for treating bacterial infections. | 2013-12-12 |
20130331451 | High Concentration Baclofen Preparations - Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/mL up to about 10 mg/mL are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration. The invention also provides methods of preparing said stable aqueous baclofen solutions. | 2013-12-12 |
20130331452 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID - Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula (I). The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and | 2013-12-12 |
20130331453 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS - The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia. | 2013-12-12 |
20130331454 | PKC-EPSILON ACTIVATOR - The present invention aims to obtain an optical isomer of DCP-LA, which shows more superior activity and is suitable for clinical utilization, and provide an agent having a superior PKC-ε activation action, a prophylactic and/or therapeutic agent for neurotransmitter release disorders, and a prophylactic and/or therapeutic agent for neuropsychiatric diseases, which contain the isomer as an active ingredient. | 2013-12-12 |
20130331455 | DEACETYLASE INHIBITORS AND USES THEREOF - The present invention provides novel compounds of formula (I) and pharmaceutical compositions thereof. The inventive compounds are useful as deacetylase inhibitors (e.g., histone deacetylase inhibitors) and may be useful in the treatment of proliferative diseases such as cancer. In particular, the inventive compounds are HDAC6 inhibitors. The invention also provide synthetic methods for preparing the inventive compounds. | 2013-12-12 |
20130331456 | INHIBITORS OF VIRAL ENTRY INTO MAMMALIAN CELLS - The present invention is related to the development of compounds and methods for inhibiting viral infection in a mammal. A pseudotype virus was developed for use in a high throughput assay for identifying nonpeptidic small molecule inhibitors that prevent viral entry into a host cell. | 2013-12-12 |
20130331457 | TREATMENT OF CANCER - Methods of treating bladder cancer are disclosed. The methods include administering to a patient a therapeutically effective amount of a 4-iodo-3-nitrobenzamide or a pharmaceutically acceptable salt thereof. | 2013-12-12 |
20130331458 | KIT OF OPHTHALMIC COMPOSITION - An ophthalmic composition kit comprising an ophthalmic container holding an ophthalmic composition comprising geranylgeranylacetone, the ophthalmic container having a surface in contact with the ophthalmic composition, the surface being at least partially or wholly made of a container material selected from the group consisting of a polyolefin, an acrylic acid resin, a terephthalic acid ester, a polycarbonate, a polymethylterpene, a fluorine resin and a glass, | 2013-12-12 |
20130331459 | A-Ring Modified 19-Nor-Vitamin D Analogs and Their Uses - Disclosed are 19-nor-vitamin D compounds, and specifically seco-A-2,19-dinor-1,25-dihydroxyvitamin D | 2013-12-12 |
20130331460 | CHRYSOPHAENTIN ANALOGS THAT INHIBIT FTSZ PROTEIN - Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, methods for using the chrysophaentin compounds, and methods for synthesizing the chrysophaentin compounds are disclosed. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains. | 2013-12-12 |
20130331461 | Stabilized Granules Containing Glyceryl Trinitrate - Solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight % glyceryl trinitrate, at least one carrier material, and at least one substance that reduces the volatility of the GTN, whereby this substance is a non-volatile ester stabilizer. | 2013-12-12 |
20130331462 | METHODS OF INHIBITING, PREVENTING, KILLING AND/OR REPELLING INSECTS USING SIMULATED BLENDS OF CHENOPODIUM - The present invention provides natural and/or simulated, synthetic, synergistic pesticidal compositions comprising terpenes, such as extracts from | 2013-12-12 |
20130331463 | METHOD FOR PRODUCING RUTILE TITANIUM OXIDE SOL - A method for producing a rutile titanium oxide sol having a particle diameter measured by dynamic light scattering of 5 nm to 100 nm, the method comprising: a process (a): mixing a tin oxalate aqueous solution, a titanium alkoxide, oxalic acid, a quaternary ammonium hydroxide, and water, while adjusting, per mole of titanium atoms, a proportion of tin atoms to be from 0.1 mol to 0.8 mol, a proportion of the oxalic acid to be from 0.01 mol to 5 mol, and a proportion of the quaternary ammonium hydroxide to be from 0.1 mol to 3.5 mol to prepare a titanium-containing aqueous solution having a concentration in terms of TiO | 2013-12-12 |
20130331464 | POLYLACTIDES COMPOSITIONS AND USES THEREOF - The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required. | 2013-12-12 |
20130331465 | FLUORINATED PROTEIN-BASED POLYMERIC CARRIERS - A biologically derived polymer that facilitates the solubilization and protection of small molecules for use in drug delivery, in which the polymer is a protein polymer. A biologically derived polymer that facilitates the solubilization and protection of small molecules for use in drug delivery, incorporating fluorinated amino acids into the protein polymer for visualization and detection by | 2013-12-12 |
20130331466 | MODIFIED SOPHOROLIPIDS AS OIL SOLUBILIZING AGENTS - A method for the development of a library of modified sophorolipids using a wide-range of chemical and enzyme catalyst tools to identify modified sophorolipids that can be used in pure form, as mixtures with other modified sophorolipids, as mixtures with natural sophorolipids, as mixtures with modified and natural sophorolipids, and as mixtures with other compounds known by one skilled in the art for use in the dispersion, solubilization or emulsification of various oil types and nutraceuticals, and modified sophorolipids for use in dispersion, solubilization or emulsification processes. | 2013-12-12 |
20130331467 | PROCESS FOR THE MODIFICATION OF CURCUMA AROMATICA ESSENTIAL OIL - essential oil is blue-black dark liquid with camphoraceous, woody, amber and spicy characteristic odour and is less valued in market, however the prepared value added products have very good shining color with the improved fragrance. The present invention relates to an efficient process for the modification of | 2013-12-12 |
20130331468 | Production Method Of O/W Emulsion Composition - The present invention provides a production method that can easily produce an O/W emulsion composition without using a special cooling apparatus and be economical. The production method of an O/W emulsion composition comprising the preparation of an emulsified part that is an O/W emulsion by emulsifying, at a temperature of 70° C. or higher, an oil phase comprising (A) a mono-branched fatty acid POE (0-60) glycerin ester, (B) a linear higher alcohol having 16 or more carbon atoms capable to form an α-gel in water with said (A), and (C) an oil component, and a part of an aqueous phase (a first aqueous phase) comprising (D) water; and the cooling of this emulsified part by mixing with stirring the remaining main aqueous phase (a second aqueous phase) at 10 to 35° C., wherein an aqueous solvent in the emulsified part is 15 mass % or less. | 2013-12-12 |
20130331469 | Method and Apparatus for Reducing CO2 in a Stream by Conversion to a Syngas for Production of Energy - A system and method for producing Syngas from the CO | 2013-12-12 |
20130331470 | POROUS POLYBENZIMIDAZOLE RESIN AND METHOD OF MAKING SAME - A porous polybenzimidazole (PBI) particulate resin is disclosed. This resin is easily dissolved at ambient temperatures and pressures. The resin is made by: dissolving a virgin PBI resin in a highly polar solvent; precipitating the dissolved PBI in a bath; and drying the precipitated PBI, the dried precipitated PBI being porous. The porous PBI resin may be dissolved by: mixing a porous PBI resin with a highly polar solvent at ambient temperatures and pressures to form a solution. | 2013-12-12 |
20130331471 | Low Melt Flow Branched Ionomers - Embodiments of the present invention include a branched aromatic ionomer, and a process of making it, by co-polymerizing a first monomer comprising an aromatic moiety and an unsaturated alkyl moiety and a second monomer represented by the general formula: | 2013-12-12 |
20130331472 | DEVICE FOR BROADHEAD AND SHARP OBJRCTS - The Broadhead Block is comprised of a closed cell, cross linked, polyethylene foam. The block is cut in the form of a cube that can be held in one's hand while being used. It has multiple sides to allow a number of objects to be secured into each side as desired. The closed cell construction of the polyethylene allows for continued penetrations with a long lasting durability. Thus providing means to loosen or tighten broad heads on the shaft of the arrow, while acting as a protective shield from the sharp blades. It acts as a wrench allowing one to grip the block instead of the sharp or broken broad heads while performing either installation or removal of said blades or broad head points from arrows. | 2013-12-12 |
20130331473 | LOW DENSITY POLYURETHANE FOAMS - Embodiments of the invention provide for low density flexible polyurethane foams are reaction products of reaction systems including at least one polyol and at least one isocyanate including at least 50% by weight of an MDI based isocyanate. The flexible polyurethane foam has a density of less than about 33 kg/m | 2013-12-12 |
20130331474 | RESIN COMPOSITION FOR LIGHT SCATTERING LAYER, LIGHT SCATTERING LAYER,AND ORGANIC ELECTROLUMINESCENCE DEVICE - Provided is a resin composition for light scattering layer for use in forming a light scattering layer of an organic EL device, including: a binder composition including at least one type of resin (A); and light scattering particles (B). In a resin composition for light scattering layer of the invention, the light scattering particles (B) have an average particle diameter of 200 nm to 500 nm in the resin composition and have a content of 20 vol % or less of particles with a particle diameter of 600 nm or more with respect to a total amount of the light scattering particles (B); and a refractive index difference between the binder composition and the light scattering particles (B) is 0.1 or more. | 2013-12-12 |
20130331475 | MODIFIED NATURAL RUBBER, METHOD FOR PRODUCING MODIFIED NATURAL RUBBER, RUBBER COMPOSITION, AND TIRE - The present invention provides a modified natural rubber obtained by adding a compound to at least one natural rubber raw material selected from the group consisting of a solid natural rubber, a natural rubber latex, and a natural rubber derivative and then irradiating the mixture of the natural rubber raw material and the compound with microwaves to graft-polymerize or attach the compound to the natural rubber raw material, a method for producing the modified natural rubber, a rubber composition containing the modified natural rubber, and a tire produced using the rubber composition. | 2013-12-12 |
20130331476 | SILOXANE HARD COATING RESIN - The present invention relates to a siloxane hard resin including alicyclic epoxy siloxane alone or a reactive monomer, which is prepared by condensation reaction of alkoxysilanes, and has a weight average molecular weight in the range of 1000 to 4000 and a molecular weight distribution of PDI 1.05 to 1.4. A siloxane hard cured article produced by photo- or thermal polymerization has high hardness by compact crosslinking of siloxane molecules having different molecular weights. | 2013-12-12 |
20130331477 | OPTICAL COMPONENT, ELECTRONIC BOARD, METHOD FOR PRODUCING THE OPTICAL COMPONENT, AND METHOD FOR PRODUCING THE ELECTRONIC BOARD - An optical component and an electrical board that have a low coefficient of linear expansion and small mold shrinkage, a method for producing the optical component, and a method for producing the electronic board are provided. An optical component includes a polymer having a repeating structural unit represented by general formula (1) | 2013-12-12 |
20130331478 | FLAME RETARDANT POLYMER COMPOSITIONS - In one aspect, the invention relates to crosslinkable, flame retardant polymer compositions are provided comprising a polyamide or polyester; a flame retardant system; a crosslinking agent; and a flame retardant system coagent. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2013-12-12 |
20130331479 | CURABLE POLYMERIC COMPOSITIONS FOR CABLE FILLING - A curable polymeric composition is herein disclosed. According to one embodiment, a curable polymeric composition comprises a thermoplastic block copolymer containing at least two polymer blocks A separated by at least one polymer block B. Each polymer block A is primarily a poly(monovinyl aromatic hydrocarbon) block, and polymer block B includes hydrogenated conjugated didne. The solid curable polymeric composition further comprises a curable functional compound compatible with polymer block A. The solid curable polymeric composition optionally comprises an initiator, a plasticizer, an antioxidant; a tackifyer and an aromatic resin. | 2013-12-12 |
20130331480 | RUBBER COMPOSITION AND TIRE PRODUCED USING SAME, AND PROCESS OF PRODUCING RUBBER COMPOSITION - Rubber composition containing at least 10 parts by mass, in 100 parts by mass of a rubber component, of a polymer component (B) containing a residue of an organic acid (A) added in a production process of the polymer, and containing from 10 to 150 parts by mass of a reinforcing filler (C), and 6 parts by mass or less in total of the residue of an organic acid (A) and an organic acid (D) used on mixing, per 100 parts by mass of the rubber component, thereby providing a rubber composition and a tire produced by using the composition, by defining the total amount of an acidic component with respect to the total mixed rubber, including an organic acid, such as stearic acid, and an organic acid contained in a residue of an emulsifier added in a production process of emulsion-polymerized SBR. | 2013-12-12 |
20130331481 | MASTERBATCH, AND METHOD OF PREPARING POLYAMIDE RESIN COMPOSITION USING MASTERBATCH - Capable of being provided are [1] a master batch comprising polyamide (X) comprising a diamine unit containing 70 mole % or more of a metaxylylenediamine unit and a dicarboxylic acid unit and an alkali compound (A), wherein an average particle diameter of the alkali compound (A) contained in the master batch is 50 μm or less; a contained number of particles having a particle diameter of exceeding 80 μm in 5 square millimeter of a cross section of the master batch is 1.5 particle or less; and a sum (m) of values obtained by multiplying a mole concentration of an alkali metal atom and a mole concentration of an alkaline earth metal atom each contained per g of the master batch by valencies thereof respectively is 60 μmol/g or more and 1710 μmol/g or less and [2] a production process for a polyamide resin composition prepared by making use of the master batch described in the above item [1]. Making use of the master batch of the present invention makes it possible to provide a polyamide resin composition which has a good appearance and a good color tone and which forms less gels in mold processing. | 2013-12-12 |
20130331482 | POLYMER COMPOSITION HAVING PHOTOALIGNABLE GROUP, LIQUID CRYSTAL ALIGNMENT FILM FORMED OF THE POLYMER COMPOSITION, AND OPTICAL DEVICE HAVING PHASE DIFFERENCE PLATE FORMED OF THE LIQUID CRYSTAL ALIGNMENT FILM - To provide a photoalignable material that can yield a photoalignable film having a high optical uniformity and no alignment defect, and is excellent in sensitivity to allow photoalignment even with exposure in a short period of time, and a liquid crystal alignment film having a high alignment stability of a liquid crystal compound from the photoalignable material. A photoalignable polymer composition containing a specific photoalignable polymer and a specific polymer that is reactive with the photoalignable polymer is manufactured, and the photoalignable film is manufactured by applying the polymer composition onto a base material or the like, drying the applied composition thereon, and irradiating the dried composition with light. Furthermore, the liquid crystal alignment film is manufactured by allowing alignment of molecules of the liquid crystal compound in the photoalignment film. | 2013-12-12 |
20130331483 | ORGANIC-INORGANIC HYBRID PAINT COMPOSITION - The present invention relates to an organic-inorganic hybrid paint composition comprising (a) an organic resin comprising an acrylic resin, a melamine resin and an epoxy resin; (b) a ceramic resin; and (c) a solvent. The paint composition of the present invention may be easily cured without a curing accelerator unlike conventional paint compositions, and it may form a paint film having generally improved properties of surface hardness and scratch resistance, as well as gloss, adhesion, boil resistance, chemical resistance, and the like. | 2013-12-12 |
20130331484 | Hybrid Adhesive and the Use Thereof in Engineered Wood Boards - The present invention relates to a hybrid adhesive, in particular for use in the production of engineered wood such as particle boards, fiber boards, plywood or glued-laminated timber, comprising at least one polycondensation adhesive, at least one polyaddition adhesive, and at least one particular, in particular a nanoparticle smaller than 500 nm, wherein the at least one particle is modified with at least one compound of the general Formula (I) R | 2013-12-12 |